Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Is it Time to Get Defensive? | Financial Sense
- It's Official: Chinese Buyers Have Left The U.S. Housing Market | ZeroHedge
- Paris Is Prologue | ZeroHedge
- Matthew Mather's Darknet Shows Reality Is Not Far From Fiction | Financial Sense
- ISIS: Oil as a Strategic Weapon | ZeroHedge
- An Angry Trader Rages: "There Is Nothing Normal About It" | ZeroHedge
- December 16th: A Date Which Will Live On In Monetary Infamy | ZeroHedge
The most relevant financial news and articles from the Internets
- The Latest: EU: Turkey deal won't provide migrants... | Business Insider
- Box Office Top 20: 'The Hunger Games' rules again | Business Insider
- High stakes for Baltimore as Freddie Gray trials begin | Business Insider
- The Latest: Jury selection starts in Freddie Gray case | Business Insider
- Former PM Kabore elected president of Burkina Faso | Business Insider
- Carson after camp tour: Absorb Syrian refugees in Mideast... | Business Insider
- Many black pastors say meeting with Trump not an... | Business Insider